Back to Search
Start Over
Thalidomide in agnogenic and secondary myelofibrosis.
- Source :
-
British journal of haematology [Br J Haematol] 2001 Nov; Vol. 115 (2), pp. 313-5. - Publication Year :
- 2001
-
Abstract
- Myelofibrosis with myeloid metaplasia (MMM) is a clonal disorder involving disregulation of angiogenesis and immunomodulatory mechanisms. Thalidomide (Thal) retains antiangiogenic, immunomodulatory and cytokine regulatory properties and recently it has been used successfully in multiple myeloma. Here, we report our experience in 10 MMM patients treated with Thal. Patients with agnogenic MMM treated in an early phase of the disease obtained significant benefits from the therapy and remain transfusion-free. In contrast, all secondary MMM failed to respond. These preliminary findings confirm that Thal plays a role in MMM therapy, although the efficacy in the different phases of the disease must be further evaluated.
- Subjects :
- Adult
Aged
Angiogenesis Inhibitors adverse effects
Female
Follow-Up Studies
Hemoglobins metabolism
Humans
Immunosuppressive Agents adverse effects
Male
Middle Aged
Primary Myelofibrosis blood
Primary Myelofibrosis complications
Thalidomide adverse effects
Treatment Outcome
Angiogenesis Inhibitors therapeutic use
Immunosuppressive Agents therapeutic use
Primary Myelofibrosis drug therapy
Thalidomide therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 0007-1048
- Volume :
- 115
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- British journal of haematology
- Publication Type :
- Academic Journal
- Accession number :
- 11703326
- Full Text :
- https://doi.org/10.1046/j.1365-2141.2001.03072.x